Similar Search Results

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R. - 2010

In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical...

Persistent link: https://www.econbiz.de/10013139118

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R. - 2010

Persistent link: https://www.econbiz.de/10012462361

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R.; Newhouse, Joseph P. - In: The Oxford handbook of the economics of the …. 2012

Persistent link: https://www.econbiz.de/10012881708

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R.; Newhouse, Joseph P. - 2010

Persistent link: https://www.econbiz.de/10014191301

An overview of Henry Grabowski's scholarly contributions

Berndt, Ernst R. - In: International journal of the economics of business 18 (2011) 2, pp. 151-154

Persistent link: https://www.econbiz.de/10009298479

Was part D a giveaway to the pharmaceutical industry?

Newhouse, Joseph P.; Seiguer, Erica; Frank, Richard G. - In: Inquiry : a journal of health care organization, … 44 (2007) 1, pp. 15-25

Persistent link: https://www.econbiz.de/10003570316

Opportunities for improving the drug development process : results from a survey of industry and the FDA

Berndt, Ernst R.; Gottschalk, Adrian H. B.; Strobeck, … - In: Innovation policy and the economy 6 (2006), pp. 91-121

Persistent link: https://www.econbiz.de/10003375038

Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation

Berndt, Ernst R.; Aitken, Murray L. - 2010

"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The landmark Waxman-Hatch Act of 1984 represented a "grand compromise" legislation that sought to balance incentives for innovation by...

Persistent link: https://www.econbiz.de/10008688817

Characterizing markets for biopharmaceutical innovations : do biologics differ from small molecules?

Trusheim, Mark; Aitken, Murray L.; Berndt, Ernst R. - 2010

Persistent link: https://www.econbiz.de/10003976203

The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts

Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - 2011

"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of...

Persistent link: https://www.econbiz.de/10009374023